SEC 13F Intelligence

Managers / Q1 2026

72 Investment Holdings, LLC

CIK 0001832749 · 72 CUMMINGS POINT ROAD, STAMFORD, CT, 06902 · 203-890-2000

Reported Value
$50M
Q1 2026
Positions
5
Filings on Record
22
2021–present window
Filed
May 15, 2026
original filing

Summary

72 Investment Holdings, LLC reported $50M in U.S.-listed holdings across 5 positions for Q1 2026.

The portfolio is heavily concentrated: PRAX alone accounts for 42.8% of reported value.

The book was largely unchanged from Q4 2025.

Portfolio Metrics

Turnover
+12.0%
vs prior filed quarter
Largest Position
+42.8%
Praxis Precision Medicines I

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’20: $742MQ4 ’20Q1 ’21: $66MQ2 ’21: $63MQ3 ’21: $80MQ3 ’21Q4 ’21: $113MQ1 ’22: $91MQ2 ’22: $65MQ2 ’22Q3 ’22: $126MQ4 ’22: $218MQ1 ’23: $211MQ1 ’23Q2 ’23: $13MQ3 ’23: $15MQ4 ’23: $23MQ4 ’23Q1 ’24: $67MQ2 ’24: $40MQ3 ’24: $47MQ3 ’24Q4 ’24: $49MQ1 ’25: $36MQ2 ’25: $38MQ2 ’25Q3 ’25: $68MQ4 ’25: $51MQ1 ’26: $50MQ1 ’26filingsflow.com

Portfolio Composition

By security type
Common Stock: 100.0%
  • Common Stock · 100.0% · $50M

Quarter-over-Quarter Changes full breakdown →

vs Q4 2025 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
LENZLENZ THERAPEUTICS INCHELD+01.02M$7M$9M
ANROALTO NEUROSCIENCE INCHELD+0667.8K+$3M$15M
PRAXPRAXIS PRECISION MEDICINES IHELD+065.9K+$2M$21M
KRROKORRO BIO INCHELD+0276.8K+$916,311$3M
CRBUCARIBOU BIOSCIENCES INCHELD+0474.1K+$146,960$900,727

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2026

5 positions
#IssuerClass% PortfolioValueShares
1PRAXPRAXIS PRECISION MEDICINES Ihistory →COM NEW42.83%$21M65.9K
2ANROALTO NEUROSCIENCE INChistory →COM SHS30.26%$15M667.8K
3LENZLENZ THERAPEUTICS INChistory →COM18.77%$9M1.02M
4KRROKORRO BIO INChistory →COM6.32%$3M276.8K
5CRBUCARIBOU BIOSCIENCES INChistory →COM1.82%$900,727474.1K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$50M5May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$51M5Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$68M5Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$38M6Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$36M6May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$49M7Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$47M7Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$40M7Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$67M7May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$23M6Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$15M5Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$13M4Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$211M5May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$218M5Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$126M5Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$65M5Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$91M6May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$113M6Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$80M4Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$63M2Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$66M2May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$742M2Feb 16, 202113F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.